DeepMed Research

St. Jude Children's Research Hospital

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1962-01-01

Employees: -

Market Cap: -

Website: http://www.stjude.org/

Clinical Trials

Stem Cell Transplantation for Children Affected With Osteopetrosis

Not Applicable

Terminated

Conditions: Osteopetrosis

Interventions: Procedure: Stem Cell Transplantation
Device: Miltenyi Biotec CliniMACS
Drug: Systemic chemotherapy and antibodies

First Posted Date: 2005-09-05

Last Posted Date: 2017-05-30

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 15

Registration Number: NCT00145587

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Use of Hydroxyurea and Magnesium Pidolate for Treatment of Sickle Cell Disease

Phase 1

Completed

Conditions: Anemia, Sickle Cell

Interventions: Drug: Magnesium Pidolate, Hydroxyurea

First Posted Date: 2005-09-02

Last Posted Date: 2017-04-26

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 16

Registration Number: NCT00143572

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Compassionate Use of Defibrotide for Patients With Veno-occlusive Disease of the Liver

Conditions: Hepatic Veno-occlusive Disease

First Posted Date: 2005-09-02

Last Posted Date: 2017-04-25

Lead Sponsor: St. Jude Children's Research Hospital

Registration Number: NCT00143546

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Prevention of Diarrhea in Patients Taking IV Irinotecan for Relapsed or Difficult to Treat Pediatric Solid Tumors

Phase 1

Completed

Conditions: Neoplasm
Diarrhea

Interventions: Drug: Irinotecan, Cefpodoxime

First Posted Date: 2005-09-02

Last Posted Date: 2017-04-26

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 20

Registration Number: NCT00143533

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies

Phase 2

Completed

Conditions: Chronic Myeloid Leukemia
Acute Lymphoblastic Leukemia
Paroxysmal Nocturnal Hemoglobinuria
Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Hodgkin's Lymphoma
Non-Hodgkin Lymphoma
Juvenile Myelomonocytic Leukemia

Interventions: Drug: Systematic chemotherapy and antibodies
Procedure: Allogeneic stem cell transplantation
Device: Miltenyi CliniMACS

First Posted Date: 2005-09-02

Last Posted Date: 2009-01-29

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 17

Registration Number: NCT00143559

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

Phase 3

Completed

Conditions: Lymphoblastic Leukemia, Acute

Interventions: Drug: Prednisone, Dexamethasone, Vincristine, Daunorubicin
Drug: Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase
Drug: Methotrexate, Cyclophosphamide, Cytarabine, Etoposide
Drug: Mercaptopurine, Imatinib
Procedure: chemotherapy, intrathecal chemotherapy
Procedure: steroid therapy, hematopoietic stem cell transplantation

First Posted Date: 2005-08-29

Last Posted Date: 2020-09-11

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 501

Registration Number: NCT00137111

Locations: 🇺🇸
St Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸
Cook Children's Medical Center, Fort Worth, Texas, United States

Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia

Phase 3

Completed

Conditions: Leukemia, Myelocytic, Acute

Interventions: Drug: Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone
Drug: Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine

First Posted Date: 2005-08-26

Last Posted Date: 2012-12-05

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 238

Registration Number: NCT00136084

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

and more 5 locations

Therapy for Children With Neuroblastoma

Phase 2

Completed

Conditions: Neuroblastoma

Interventions: Drug: Gefitinib, Irinotecan, Cycophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, Carboplatin, Melphalan, 13-cis retinoic acid
Procedure: Radiation therapy, Surgery, Peripheral Stem cell transplant

First Posted Date: 2005-08-25

Last Posted Date: 2008-06-03

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 23

Registration Number: NCT00135135

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors

Phase 1

Completed

Conditions: Neuroblastoma
Glioblastoma
Rhabdomyosarcomas
Osteosarcoma

Interventions: Drug: Irinotecan (Camptosar), Gefitinib (Iressa)

First Posted Date: 2005-08-19

Last Posted Date: 2012-04-17

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 19

Registration Number: NCT00132158

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Trial of Oral Glutamine in Patients With Sickle Cell Anemia

Phase 2

Terminated

Conditions: Anemia, Sickle Cell

Interventions: Drug: Placebo
Drug: Glutamine

First Posted Date: 2005-08-18

Last Posted Date: 2017-04-26

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 27

Registration Number: NCT00131508

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy